FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 338:205-206 January 15, 1998 Number 3

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited

Edited by Marc Hertzman and Douglas E. Feltner. 454 pp. New York, New York University Press, 1997. $75. ISBN 0-8147-3532-0.

Psychopharmacology trials have gone through a big boom in the past 10 years. According to a recent list, there are 294 products that act on the central nervous system in the worldwide pharmaceutical pipeline, and approximately 40 percent of them are psychopharmacologic agents for psychiatric disorders. Therefore, it would be important and timely to recommend a definitive book in this area. This is not the definitive book, however. Some chapters are worth reading, but I did not like others. For readers interested in the scientific aspects of psychopharmacology trials, Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines, edited by R.F. . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.